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Dr Lars G. Svensson (Cleveland, Ohio).Dr D’Onofrio has pre-
sented one of the largest series on the transapical approach with
good results. The 8.3% hospital mortality and 3% major stroke
rate for these high-risk patients, with a significant atherosclerotic
load, is remarkably good. Having been involved in the original
transapical approach research with Drs Mike Mack, Todd Dewey,
Thomas Walther, Fred Mohr, John Webb and his team, and from
the Edwards team, Mike Mussallem, Larry Woods, Jill Trekell,
Jody Akins, and Mark Dehdastian starting in 2004, it is very grat-
ifying, despite our early hiccups, to see how the technology has
matured and improved.
It is incumbent on me to compare this presentation with the
results from the PARTNER A study, presented at the American
College of Cardiology meeting by our upcoming president, Craig
Smith. In that study, with the transfemoral approach as the de-
fault approach, if access was possible, as in your Italian study,
transapical patients had more cerebrovascular disease, carotid
endarterectomies, previous coronary artery bypass grafting, per-
cutaneous coronary intervention, porcelain aorta, atrial fibrilla-
tion, obviously peripheral vascular disease, and more severe
aortic valve stenoses, all of which are evidence of greater athero-
sclerotic load and also risk for death and stroke. The mortality
and stroke rates in the PARTNER A study were equivalent to
the TA arm; in other words, open aortic valve replacement was
equivalent to the TA-TAVI.
Given that in Italy and the United States the transfemoral ap-
proach is the default choice for patients but has not been compared
with the transapical approach, what is the likelihood in Italy that
you could do a prospective randomized trial comparing transfe-
moral versus transapical and also including the new approach,
the transaortic approach? Do you have any registry data yet for
Italy for the transaortic procedure even though the current device
was neither designed for this nor is ideal for the transaortic
approach?
Clearly we need to aim to reduce the stroke rate to the superb
low risk of 1.4% noted in the open aortic valve replacement control
group in the transfemoral part of the PARTNER A trial. Have you
had the opportunity to try any of the new stroke filter or carotid
protection devices, including using the EMBOL-X filter (Edwards
Lifesciences), particularly for the transaortic procedure?The Journal of Thoracic and CaDr D’Onofrio. Dr Svensson, thank you for your comments and
for these questions.
The great majority of centers that participated in this study fol-
lowed a transfemoral-first policy. This means that about 90% of
these patients underwent screening for a transfemoral procedure
and, since they were not considered suitable for a transfemoral ap-
proach, they went for a transapical valve implantation. Conse-
quently these patients had a higher risk profile in terms of
peripheral arterial disease, stroke, and mesenteric ischemia. Actu-
ally, we observed a low incidence of stroke and a low incidence of
access-related complications, for example, major bleeding from
the left ventricular apex. If we compare these results with the in-
cidence of major vascular complications that were reported in
the SOURCE and in the PARTNER trial that ranged from 10%
to 15%, the result is that to date there is no strong evidence that
supports the transfemoral-first policy. Unfortunately, the PART-
NER trial was not powered enough to compare the transfemoral
versus the transapical approach. I think that all cardiac surgeons
should be well aware of this problem when discussing TAVI cases
with cardiologists.
We do not have to necessarily go straight for a transfemoral ap-
proach first and then, only if the patient is not suitable, choose the
transapical technique, sincewe do not have evidence to support this
strategy. I think that we should determine the best approach for ev-
ery single patient. This registry gave us the opportunity to create
a good network of centers that perform transapical procedures.
The idea of a prospective randomized trial is excellent, and I
hope that we will be able to do that in the near future.
Dr Svensson. Just to address that, there are plans ahead to do
a European prospective randomized trial. You might want to dis-
cuss this with Thomas Walther. Obviously in some centers it
will be difficult, but for those who have the option of either proce-
dure, you might want to talk to him. I understand there are plans at
Edwards to finance this. So I would encourage those centers in
Italy that can to get involved with a prospective randomized trial.
Dr D’Onofrio. I will discuss this issue with my Italian col-
leagues. Thank you.
Regarding your questions about the EMBOL-X filters and
transaortic approach, we do not have data in this registry about
transaortic procedures, and we did not collect data about the use
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